About Halucenex
Halucenex is a Healthcare company based in Windsor (Canada) founded in 2019, and was acquired by Creso Pharma in March 2021. Psychedelic drugs for mental illness treatment are developed by Halucenex. The company has 2 employees. Its focus areas include Life Sciences, Neurology, Drugs and Psychiatric.
Company details
Founded in 2019 and based in Windsor, Canada, Halucenex is involved in the biotechnology sector, where psychedelic compounds such as psilocybin and its derivatives are developed for addressing PTSD and anxiety. Operations focus on therapeutic applications of these substances, with research exploring their roles in managing depression, addiction, mood disorders, and related conditions through guided psychedelic therapy protocols.
- Headquarters Windsor, Canada
- Employees 2
- Stage Acquired
- SectorsHealthcare
- Website halucenex.com
- Social LinkedIn
- Acquired by Creso Pharma (Mar 2021)
- Investors
- Employee Count2
- Acquired byCreso Pharma
(Mar 2021)
Investors in Halucenex
Halucenex has secured backing from 1 investor. Prominent investors backing the company include Creso Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Cannabinoid therapeutics are developed for human and veterinary health applications. | 2015 | cresopharma.com | Perth, Australia |
Investor details for Halucenex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Halucenex
2 dated milestones of Halucenex across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Halucenex is founded.
- Exit Acquired by Creso Pharma.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Halucenex
Complete news archive for Halucenex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Halucenex
Halucenex was founded in 2019.
Halucenex is headquartered in Windsor, Canada. It is registered at Windsor, Ontario, Canada.
Halucenex has 2 employees.
Founded in 2019 and based in Windsor, Canada, Halucenex is involved in the biotechnology sector, where psychedelic compounds such as psilocybin and its derivatives are developed for addressing PTSD and anxiety. Operations focus on therapeutic applications of these substances, with research exploring their roles in managing depression, addiction, mood disorders, and related conditions through guided psychedelic therapy protocols.
Halucenex has 1 investor. Key investors include Creso Pharma.
Yes. Halucenex was acquired by Creso Pharma in March 2021.